BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 34058457)

  • 1. Practical considerations for testing the effects of cannabidiol on human anxiety.
    Leen-Feldner EW; Bynion TM; Gournay R; Bonn-Miller MO; Feldner MT
    J Anxiety Disord; 2021 Aug; 82():102429. PubMed ID: 34058457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluorinated Cannabidiol Derivatives: Enhancement of Activity in Mice Models Predictive of Anxiolytic, Antidepressant and Antipsychotic Effects.
    Breuer A; Haj CG; Fogaça MV; Gomes FV; Silva NR; Pedrazzi JF; Del Bel EA; Hallak JC; Crippa JA; Zuardi AW; Mechoulam R; Guimarães FS
    PLoS One; 2016; 11(7):e0158779. PubMed ID: 27416026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of cannabidiol on worry and anxiety among high trait worriers: a double-blind, randomized placebo controlled trial.
    Gournay LR; Ferretti ML; Bilsky S; Vance E; Nguyen AM; Mann E; Williams P; Leen-Feldner EW
    Psychopharmacology (Berl); 2023 Oct; 240(10):2147-2161. PubMed ID: 37552290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview.
    Mandolini GM; Lazzaretti M; Pigoni A; Oldani L; Delvecchio G; Brambilla P
    Epidemiol Psychiatr Sci; 2018 Aug; 27(4):327-335. PubMed ID: 29789034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of prior foot shock stress and Δ
    Rock EM; Limebeer CL; Petrie GN; Williams LA; Mechoulam R; Parker LA
    Psychopharmacology (Berl); 2017 Jul; 234(14):2207-2217. PubMed ID: 28424834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug.
    Schier AR; Ribeiro NP; Silva AC; Hallak JE; Crippa JA; Nardi AE; Zuardi AW
    Braz J Psychiatry; 2012 Jun; 34 Suppl 1():S104-10. PubMed ID: 22729452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cannabis, a cause for anxiety? A critical appraisal of the anxiogenic and anxiolytic properties.
    Sharpe L; Sinclair J; Kramer A; de Manincor M; Sarris J
    J Transl Med; 2020 Oct; 18(1):374. PubMed ID: 33008420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Double-Blind, Randomized, Placebo-Controlled Test of the Effects of Cannabidiol on Experiences of Test Anxiety Among College Students.
    Stanley TB; Ferretti ML; Bonn-Miller MO; Irons JG
    Cannabis Cannabinoid Res; 2023 Dec; 8(6):1090-1099. PubMed ID: 35861792
    [No Abstract]   [Full Text] [Related]  

  • 9. Cannabidiol as a Potential Treatment for Anxiety Disorders.
    Blessing EM; Steenkamp MM; Manzanares J; Marmar CR
    Neurotherapeutics; 2015 Oct; 12(4):825-36. PubMed ID: 26341731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cannabidiol as a Potential Treatment for Anxiety and Mood Disorders: Molecular Targets and Epigenetic Insights from Preclinical Research.
    Melas PA; Scherma M; Fratta W; Cifani C; Fadda P
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33668469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system.
    Campos AC; Ortega Z; Palazuelos J; Fogaça MV; Aguiar DC; Díaz-Alonso J; Ortega-Gutiérrez S; Vázquez-Villa H; Moreira FA; Guzmán M; Galve-Roperh I; Guimarães FS
    Int J Neuropsychopharmacol; 2013 Jul; 16(6):1407-19. PubMed ID: 23298518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of intra-prelimbic prefrontal cortex injection of cannabidiol on anxiety-like behavior: involvement of 5HT1A receptors and previous stressful experience.
    Fogaça MV; Reis FM; Campos AC; Guimarães FS
    Eur Neuropsychopharmacol; 2014 Mar; 24(3):410-9. PubMed ID: 24321837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report.
    Crippa JA; Derenusson GN; Ferrari TB; Wichert-Ana L; Duran FL; Martin-Santos R; Simões MV; Bhattacharyya S; Fusar-Poli P; Atakan Z; Santos Filho A; Freitas-Ferrari MC; McGuire PK; Zuardi AW; Busatto GF; Hallak JE
    J Psychopharmacol; 2011 Jan; 25(1):121-30. PubMed ID: 20829306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sex-dependent differences in the anxiolytic-like effect of cannabidiol in the elevated plus-maze.
    Fabris D; Carvalho MC; Brandão ML; Prado WA; Zuardi AW; Crippa JA; de Oliveira AR; Lovick TA; Genaro K
    J Psychopharmacol; 2022 Dec; 36(12):1371-1383. PubMed ID: 36239039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cannabidiol in medical marijuana: Research vistas and potential opportunities.
    Rong C; Lee Y; Carmona NE; Cha DS; Ragguett RM; Rosenblat JD; Mansur RB; Ho RC; McIntyre RS
    Pharmacol Res; 2017 Jul; 121():213-218. PubMed ID: 28501518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabidiol disrupts conditioned fear expression and cannabidiolic acid reduces trauma-induced anxiety-related behaviour in mice.
    Assareh N; Gururajan A; Zhou C; Luo JL; Kevin RC; Arnold JC
    Behav Pharmacol; 2020 Sep; 31(6):591-596. PubMed ID: 32483052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The acute effects of cannabidiol on emotional processing and anxiety: a neurocognitive imaging study.
    Bloomfield MAP; Yamamori Y; Hindocha C; Jones APM; Yim JLL; Walker HR; Statton B; Wall MB; Lees RH; Howes OD; Curran VH; Roiser JP; Freeman TP
    Psychopharmacology (Berl); 2022 May; 239(5):1539-1549. PubMed ID: 35445839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A scoping review of the use of cannabidiol in psychiatric disorders.
    Kirkland AE; Fadus MC; Gruber SA; Gray KM; Wilens TE; Squeglia LM
    Psychiatry Res; 2022 Feb; 308():114347. PubMed ID: 34952255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Citalopram and Cannabidiol: In Vitro and In Vivo Evidence of Pharmacokinetic Interactions Relevant to the Treatment of Anxiety Disorders in Young People.
    Anderson LL; Doohan PT; Oldfield L; Kevin RC; Arnold JC; Berger M; Amminger GP; McGregor IS
    J Clin Psychopharmacol; 2021 Sep-Oct 01; 41(5):525-533. PubMed ID: 34121064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of cannabidiol on symptoms induced by the recall of traumatic events in patients with posttraumatic stress disorder.
    Bolsoni LM; Crippa JAS; Hallak JEC; Guimarães FS; Zuardi AW
    Psychopharmacology (Berl); 2022 May; 239(5):1499-1507. PubMed ID: 35029706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.